Verrica Pharmaceuticals Targets COVE-3 Initiation by Mid-2026

Verrica Pharmaceuticals announced its target to initiate the COVE-3 trial by mid-2026, alongside reporting a 12.1% sequential rise in dispensed YCANTH units during the first quarter. This update provides insight into the company's development pipeline and product performance.